Severe sustained cholestatic hepatitis following temozolomide in a patient with glioblastoma multiforme: case study and review of data from the FDA adverse event reporting system-Reference-Cited by-同舟云学术

Severe sustained cholestatic hepatitis following temozolomide in a patient with glioblastoma multiforme: case study and review of data from the FDA adverse event reporting system

Published:2012-03-06 Issue:5 Volume:14 Page:541-546
ISSN:1522-8517
Container-title:Neuro-Oncology
language:en
Short-container-title:Neuro-Oncology

Author:

Sarganas G.,Orzechowski H. D.,Klimpel A.,Thomae M.,Kauffmann W.,Herbst H.,Bronder E.,Garbe E.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Neurology (clinical),Oncology

Link

http://academic.oup.com/neuro-oncology/article-pdf/14/5/541/4904696/nos056.pdf

Reference14 articles.

1. Brain Tumors

2. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

3. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma

4. Drug induced immune haemolytic anaemia in the Berlin Case-Control Surveillance Study

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mutations in the TP53, VEGFA, and CTH Genes as Key Molecular Markers for the Diagnosis of Glioblastoma;Cureus;2024-05-27

2. Gastrointestinal and Hepatic Complications in Cancer Patients;Holland‐Frei Cancer Medicine;2022-10-21

3. An overview of current results with the vincristine-irinotecan-temozolomide combination with or without bevacizumab in pediatric, adolescence and adult solid tumors;Critical Reviews in Oncology/Hematology;2021-10

4. Chlorogenic acid sustained-release gel for treatment of glioma and hepatocellular carcinoma;European Journal of Pharmaceutics and Biopharmaceutics;2021-09

5. Phase 1 trial of ralimetinib (LY2228820) with radiotherapy plus concomitant temozolomide in the treatment of newly diagnosed glioblastoma;Radiotherapy and Oncology;2021-01